Overview

Intratumoral CAN2109 in Subjects With Solid Tumors

Status:
RECRUITING
Trial end date:
2026-05-30
Target enrollment:
Participant gender:
Summary
A phase 1, dose escalation, open-label study of intratumoral CAN2109 in subjects with unstable or metastatic advanced solid tumors or lymphomas.
Phase:
PHASE1
Details
Lead Sponsor:
Canwell Biotech Limited